Fidelis Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Fidelis Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$965K	Buy	1,249 +4	+0.3%	+$3.06K	0.07%	214
2025 Q4	$961K	Buy	1,245 +6	+0.5%	+$4.08K	0.07%	207
2025 Q3	$697K	Buy	+1,239	New	+$701K	0.05%	248
2025 Q2	–	Sell	-427	Closed	-$257K	–	464
2025 Q1	$257K	Sell	427 -20	-4%	-$13.8K	0.03%	351
2024 Q4	$298K	Sell	447 -54	-11%	-$45.3K	0.03%	333
2024 Q3	$472K	Sell	501 -33	-6%	-$36.7K	0.06%	243
2024 Q2	$570K	Buy	534 +114	+27%	+$111K	0.08%	195
2024 Q1	$404K	Buy	420 +56	+15%	+$53.2K	0.06%	237
2023 Q4	$320K	Buy	+364	New	+$300K	0.07%	236

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Fidelis Capital Partners's REGN Position: Q1 2026 in Review

Fidelis Capital Partners increased its Regeneron Pharmaceuticals (REGN) stake by 0.32% in Q1 2026, buying an estimated $3.06K and bringing the position to 1,249 shares worth $965K. The position accounts for 0.07% of the portfolio, ranked #214.

Fidelis Capital Partners first reported a position in REGN in Q4 2023 and has held it in 9 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Fidelis Capital Partners held 1,249 shares of Regeneron Pharmaceuticals worth $965K as of Q1 2026.
Fidelis Capital Partners bought 4 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.06K.
Regeneron Pharmaceuticals made up 0.07% of Fidelis Capital Partners's portfolio in Q1 2026, its #214 holding.
Fidelis Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Fidelis Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.